Latest News from: Rutgers Cancer Institute of New Jersey

Add to Favorites Subscribe Share
newswise-fb-share-

Cervical Cancer Awareness Month

Rutgers Cancer Institute of New Jersey

January is Cervical Cancer Awareness Month. A Rutgers Cancer Institute of New Jersey expert shares insight on prevention and early detection of this disease.

Channels: Cancer, OBGYN, Women's Health,

Released:
2-Jan-2020 3:00 PM EST
Released:
17-Dec-2019 10:15 AM EST
Video-Only
Newswise: Novel Cell-Based Therapy Induces Cell Death in Sensitive and Resistant Non-Hodgkin Lymphoma Models

Novel Cell-Based Therapy Induces Cell Death in Sensitive and Resistant Non-Hodgkin Lymphoma Models

Rutgers Cancer Institute of New Jersey

Investigators at Rutgers Cancer Institute of New Jersey have found that a treatment based on a novel cellular product programmed to deliver an overabundance of chimeric antigen receptor causes cell death in non-Hodgkin lymphoma models that are sensitive or resistant to standard therapies.

Channels: All Journal News, Cancer, Cell Biology, Immunology,

Released:
16-Dec-2019 8:05 AM EST
Video-Only
Newswise: Analysis of Different Treatment Strategies for Non-Invasive Breast Cancer Shows Radiation Treatment Alone is Cost-Effective

Analysis of Different Treatment Strategies for Non-Invasive Breast Cancer Shows Radiation Treatment Alone is Cost-Effective

Rutgers Cancer Institute of New Jersey

Rutgers Cancer Institute of New Jersey investigators evaluated all treatment strategies for both standard-risk and good-risk ductal carcinoma in-situ and found the most commonly recommended combination treatment for DCIS represents low-value care, while radiation therapy alone was cost-effective.

Channels: All Journal News, Cancer, Healthcare, Women's Health, Local - New Jersey, Medical Meetings,

Released:
11-Dec-2019 2:05 PM EST
Research Results
Newswise: Small Mutations Identified through Deep DNA Sequencing for AML and MDS

Small Mutations Identified through Deep DNA Sequencing for AML and MDS

Rutgers Cancer Institute of New Jersey

Deep DNA sequencing analysis conducted by Rutgers Cancer Institute of New Jersey investigators examining genomic differences within tumors for prediction of disease relapse in certain hematologic malignancies has identified small mutations. These may help further guide treatment decision making for patients.

Channels: All Journal News, Blood, Cancer, Genetics, Medical Meetings,

Released:
9-Dec-2019 5:05 PM EST
Research Results
Newswise: Retrospective Analysis Shows Proton Therapy Well Tolerated in Patients Undergoing Breast Conserving Surgery

Retrospective Analysis Shows Proton Therapy Well Tolerated in Patients Undergoing Breast Conserving Surgery

Rutgers Cancer Institute of New Jersey

Investigators at Rutgers Cancer Institute of New Jersey conducted a retrospective review of patients treated with proton therapy following breast-conserving surgery and found acceptable toxicity rates along with good-to-excellent patient-reported cosmetic outcomes.

Channels: All Journal News, Cancer, Healthcare, Surgery, Women's Health, Medical Meetings,

Released:
9-Dec-2019 4:20 PM EST
Research Results
Newswise: Likelihood of Prenatal Screening for Blood Disorders Varies Between Type of Healthcare Provider

Likelihood of Prenatal Screening for Blood Disorders Varies Between Type of Healthcare Provider

Rutgers Cancer Institute of New Jersey

A Rutgers Cancer Institute of New Jersey investigator and other collaborators examined prenatal screening practices for blood disorders between different types of care providers and found different variations in prenatal guidance.

Channels: Blood, Cancer, OBGYN, Women's Health, Medical Meetings,

Released:
5-Dec-2019 9:00 AM EST
Research Results
Newswise: Addition of Post-Transplant Chemotherapy to Standard Immune Treatment Shows Increase of Allogeneic Transplant Patients in Remission

Addition of Post-Transplant Chemotherapy to Standard Immune Treatment Shows Increase of Allogeneic Transplant Patients in Remission

Rutgers Cancer Institute of New Jersey

Rutgers Cancer Institute of New Jersey investigators compared outcomes for allogeneic stem cell transplant patients when post-transplant cyclophosphamide (PCy) was added as part of standard treatment than if standard treatment was given alone. Results showed an increase in the number of patients who were free of disease and off immunosuppression at one-year in the PCy cohort.

Channels: Cancer, Immunology, Surgery, Transplantation, Medical Meetings,

Released:
5-Dec-2019 8:45 AM EST
Research Results
Newswise: Rutgers Cancer Institute Researchers Identify Novel Gene Associated with Prognosis in Aggressive form of Ovarian Cancer

Rutgers Cancer Institute Researchers Identify Novel Gene Associated with Prognosis in Aggressive form of Ovarian Cancer

Rutgers Cancer Institute of New Jersey

Investigators at Rutgers Cancer Institute of New Jersey have determined that an overabundance of a novel gene known as ADNP in an aggressive form of ovarian cancer may serve as a prognostic tool.

Channels: Cancer, Women's Health, Local - New Jersey, All Journal News,

Released:
5-Dec-2019 8:00 AM EST
Research Results
Newswise: Retrospective Analysis Identifies Need for Better Classification of Rare Lymphoma

Retrospective Analysis Identifies Need for Better Classification of Rare Lymphoma

Rutgers Cancer Institute of New Jersey

In what is believed to be one of the largest studies of a rare disorder known as primary cutaneous gamma delta T-cell lymphoma, Rutgers Cancer Institute investigators and other collaborators examined characteristics, treatment patterns and outcomes and determined accurate diagnosis of the disease requires ongoing analysis.

Channels: Medical Meetings, All Journal News, Cancer, Healthcare, Local - New Jersey,

Released:
4-Dec-2019 8:00 AM EST
Research Results


0.85744